MARLBOROUGH, Mass.--(EON: Enhanced Online News)--Advanced Cell Technology, Inc. (“ACT”)(OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that it will webcast its Annual Shareholders’ Meeting to be held on Tuesday, October 22nd at the Hyatt Regency Suites, Palm Springs, 285 N. Palm Canyon Drive, Palm Springs, Calif. The meeting is open to shareholders of record as of August 23, 2013. The webcast will begin at 9 a.m. PDT, after the Company completes the formal portion of the meeting, where results of proxy voting will be announced. At that time, members of the management team will deliver a Company presentation and address questions from shareholders. Questions will be taken from both members of the live audience as well as electronically from the webcast.
The webcast will be available live and for replay by webcast at: http://us.meeting-stream.com/advancedcelltechnology102213
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The company is conducting various clinical trials for treating macular degeneration, and has a preclinical development pipeline focused on products for eye diseases, autoimmune and inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent stem cell platforms comprising embryonic stem cell and induced pluripotent stem cell (iPSC) platforms; and other cell therapy research programs, such as opthamology, autoimmune/inflammation, and platelet programs. Advanced Cell Technology, Inc. develops and maintains an intellectual property portfolio, with ownership or licensing of approximately 37 issued patents and approximately 190 patent applications pending in the field of regenerative medicine and stem cell therapy. The company is headquartered in Marlborough, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2012. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.